- Home
- CYRX vs LRMR Comparison
CYRX vs LRMR Comparison
Compare CYRX & LRMR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CYRX
- LRMR
- Stock Information
- Founded
- CYRX 1999
- LRMR N/A
- Country
- CYRX United States
- LRMR United States
- Employees
- CYRX N/A
- LRMR N/A
- Industry
- CYRX Biotechnology: Pharmaceutical Preparations
- LRMR Biotechnology: Pharmaceutical Preparations
- Sector
- CYRX Health Care
- LRMR Health Care
- Exchange
- CYRX Nasdaq
- LRMR Nasdaq
- Market Cap
- CYRX 405.4M
- LRMR 426.9M
- IPO Year
- CYRX N/A
- LRMR N/A
- Fundamental
- Price
- CYRX $6.55
- LRMR $6.16
- Analyst Decision
- CYRX Buy
- LRMR Strong Buy
- Analyst Count
- CYRX 7
- LRMR 8
- Target Price
- CYRX $13.14
- LRMR $19.63
- AVG Volume (30 Days)
- CYRX 416.3K
- LRMR 744.4K
- Earning Date
- CYRX 11-07-2024
- LRMR 10-30-2024
- Dividend Yield
- CYRX N/A
- LRMR N/A
- EPS Growth
- CYRX N/A
- LRMR N/A
- EPS
- CYRX N/A
- LRMR N/A
- Revenue
- CYRX $226,113,000.00
- LRMR N/A
- Revenue This Year
- CYRX $0.34
- LRMR N/A
- Revenue Next Year
- CYRX $8.47
- LRMR N/A
- P/E Ratio
- CYRX N/A
- LRMR N/A
- Revenue Growth
- CYRX N/A
- LRMR N/A
- 52 Week Low
- CYRX $5.32
- LRMR $3.09
- 52 Week High
- CYRX $20.11
- LRMR $13.68
- Technical
- Relative Strength Index (RSI)
- CYRX 36.27
- LRMR 34.63
- Support Level
- CYRX $7.18
- LRMR $5.92
- Resistance Level
- CYRX $8.79
- LRMR $6.60
- Average True Range (ATR)
- CYRX 0.61
- LRMR 0.69
- MACD
- CYRX -0.12
- LRMR -0.32
- Stochastic Oscillator
- CYRX 0.00
- LRMR 4.45
About CYRX CryoPort Inc.
CryoPort Inc is a leader serving the life sciences industry as a provider of integrated temperature-controlled supply chain solutions supporting the life sciences in the biopharma/pharma, animal health, and reproductive medicine markets. Geographically the company operates in the Americas, Europe, the Middle East and Africa (EMEA), and Asia Pacific (APAC), generating a majority of its revenue from the Americas.
About LRMR Larimar Therapeutics Inc.
Larimar Therapeutics Inc is a clinical-stage biotechnology company focused on developing treatments for patients suffering from complex rare diseases using novel cell-penetrating peptide technology platform. Its lead product candidate, CTI-1601, is a subcutaneously administered, recombinant fusion protein intended to deliver human frataxin (FXN) an essential protein, to the mitochondria of patients with Friedreich's ataxia.